ARSA and metachromatic leukodystrophy: The genetic diagnosis can be highly beneficial in terms of identifying therapeutic targets, thus allowing, for example, the administration of the relevant recombinant enzyme (enzyme replacement therapy), as done for the treatment of metachromatic leukodystrophy due to Arylsulfatase A (ARSA) mutations [126].